XOMA Ltd. (Nasdaq: XOMA) 35.3% HIGHER; following yesterday's late day spike on news that XOMA's bacterial cell expression technology licensee UCB S.A. has received FDA approval to market CIMZIA(r) (certolizumab pegol).
XOMA will receive royalty payments on sales of CIMZIA for this indication and will continue to receive royalties on sales of CIMZIA for the treatment of moderate to severe Crohn's disease, for which it was approved in April 2008.
Momentum is continuing today as news hit that Zymeworks has entered into a research agreement with XOMA Ltd.
xoma ltdMorning Movers 5/15: XOMA, ADY, EXEL, DRYS, WX, LVS, HIG Higher;...StreetInsider.com News Articles Fri, 05/15/2009 - 07:43
|
